Tysabri revenue trends
In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 million, a ~6% fall YoY and a 2% fall QoQ. In 3Q17, Tysabri accounted for ~17.9% of Biogen’s net product revenue.
Lower unit sales volumes were the primary cause of the Tysabri revenue in 3Q17. In 3Q17, US Tysabri unit sales volumes fell 6%. Higher Tysabri prices were offset by higher discounts and allowances.
Between 2Q17 and 3Q17, in the European market, the number of Tysabri patients rose 2%. Biogen expects Tysabri demand to be stable worldwide for the rest of 2017, due to patient growth in international markets. Global growth in Tysabri patients is expected to balance a modest fall in Tysabri patients in the US market.
Fampyra and Zinbryta revenue trends
In 3Q17, Biogen generated revenue of ~$24.3 million and $14.2 million from sales of Fampyra and Zinbryta. In 3Q17, Fampyra revenue grew 15% growth YoY and 7% growth QoQ. In 3Q17, Zinbryta revenue fell 11% QoQ.
Biogen’s peers in the multiple sclerosis drug market include Bayer, Novartis, Teva Pharmaceutical, Sanofi, Pfizer, and Merck. The Health Care Select Sector SPDR ETF (XLV) invests ~2.2% of its portfolio in Biogen.